Ascentage Pharma Announces 2022 Interim Results
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com
📰 Drug Programs News
Page 8 - Drug Programs News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Drug Programs. Real-time updates on events, politics, business and more.
Shasta County drug, alcohol deaths rise as new treatments emerge
Here is how the people on the front lines of Shasta Countys drug war are dealing with rising drug and alcohol overdoses and deaths.
Source: redding.com
Shasta County drug, alcohol deaths rise as new treatments emerge
Here is how the people on the front lines of Shasta Countys drug war are dealing with rising drug and alcohol overdoses and deaths.
Source: siskiyoudaily.com
Shasta County drug, alcohol deaths rise as new treatments emerge
Here is how the people on the front lines of Shasta Countys drug war are dealing with rising drug and alcohol overdoses and deaths.
Source: mtshastanews.com
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
Source: prnewswire.com
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
SUZHOU, China, ROCKVILLE, Md. and SAN FRANCISCO, July 20, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic,...
Source: asiaone.com
EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com
ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
Source: prnewswire.com